Mercodia Lispro NL-ELISA

Thursday, 04 April, 2019 | Supplied by: Sapphire Bioscience

Mercodia’s Lispro Northern Lights (NL)-ELISA provides a chemiluminescent method for the quantitative determination of insulin lispro.

Lispro is a rapid-acting insulin analogue that was first introduced in 1996 to treat people with diabetes. Mercodia’s Lispro NL-ELISA, a novel pharmacokinetics (PK) assay, is both sensitive and specific for determination of insulin lispro. With pre-diluted calibrators in serum matrix at six levels, as evidenced by the robust assay performance characteristics, this method is suitable for multiple phases of drug development and meets the requirements of EMA and FDA validation.

The Lispro NL-ELISA Kit enables a broad measuring range, is fully validated for use with human and porcine samples, and requires a low sample volume of 10 μL. The ELISA kit has no cross-reactivity to endogenous insulin or other insulin analogues and has no interference from insulin auto-antibodies. Additionally, the kit gives results in just 2 h 15 min.

Phone: 02 9698 2022
Related Products

Fluidic Analytics Fluidity One-W for protein analysis

The Fluidity One-W instrument, from Fluidic Analytics, is able to assess on-target protein...

Integrated DNA Technologies oPools Oligo Pools

Integrated DNA Technologies (IDT) has launched oPools Oligo Pools — ready-to-use pools of...

Phase Genomics Hi-C proximity ligation kits

Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale...

  • All content Copyright © 2019 Westwick-Farrow Pty Ltd